Researchers at Zhongshan Hospital, Fudan University, have uncovered a surprising connection between a common thyroid hormone and nerve damage in people with type 2 diabetes. 
Their study, published in the Journal of Clinical Endocrinology and Metabolism, looked at 1422 hospitalized patients, all with normal thyroid function, to see how free triiodothyronine—or FT3—might play a role in diabetic peripheral neuropathy, or DPN. This condition causes pain, numbness, and weakness in the hands and feet due to nerve damage from high blood sugar over time. Doctors often diagnose it through symptoms and tests like electromyography, which measures nerve signals. What they found could change how we think about managing diabetes complications.
Uncovering the Patient Profile
The team carefully checked every patient with detailed nerve tests, including nerve conduction velocity, distal motor and sensory latency, and amplitudes of muscle and sensory nerve responses. Out of the 1422 participants, 519—or 36.5%—had DPN based on their symptoms and test results. These patients stood out in several ways compared to those without DPN. They had lived with diabetes much longer, struggled more with blood sugar control, and carried less body weight on average. On top of that, they showed higher rates of other diabetes issues like retinopathy, nephropathy, and heart disease. All these differences held up with strong statistical significance, suggesting a higher risk in this group.
FT3 Levels Tell a Compelling Story
FT3 levels were noticeably lower in DPN patients at 4.08 pmol/L versus 4.39 pmol/L in those without the condition. This gap proved highly significant. The reserachers found FT3 linked directly to nerve function tests. In DPN patients, higher FT3 correlated with better nerve conduction speeds and stronger signal amplitudes, while it tied to shorter delays in nerve responses. Even after adjusting for factors like age, diabetes duration, blood sugar levels, and other health issues, the protective link between FT3 and lower DPN risk remained solid. This suggests FT3 might act as a marker or even a target for prevention.
Genetic Evidence Seals the Deal
To go beyond simple associations, the team turned to Mendelian randomization. This analysis confirmed that genetically lower FT3 levels causally raise DPN risk in type 2 diabetes patients. Such findings add weight because they rule out reverse causation or hidden biases common in observational studies. For physicians treating diabetes, this opens doors to routine FT3 checks in euthyroid patients, especially those with early nerve symptoms or multiple complications.
What This Means for Clinical Practice
This study highlights low FT3 as a potential risk factor for DPN, urging doctors to consider thyroid optimization alongside glucose control. While more studies will test interventions like FT3-boosting therapies, the results already call for integrated care that screens for subtle hormone shifts. In everyday practice, spotting low FT3 could help flag high-risk patients early, potentially slowing neuropathy's march and improving quality of life.